Difference between revisions of "Gene set analysis methods: a systematic comparison"
(First version) |
(→Study design and evidence level) |
||
Line 32: | Line 32: | ||
=== Study design and evidence level === | === Study design and evidence level === | ||
==== General aspects ==== | ==== General aspects ==== | ||
− | |||
* The authors compared four different methods: | * The authors compared four different methods: | ||
** Gene Set Enrichment Analysis (GSEA) | ** Gene Set Enrichment Analysis (GSEA) | ||
Line 38: | Line 37: | ||
** sigPathway, and | ** sigPathway, and | ||
** Correlation Adjusted Mean RAnk (CAMERA). | ** Correlation Adjusted Mean RAnk (CAMERA). | ||
+ | * The authors consider different sizes of the gene sets | ||
+ | * The authors consider different proportions of regulated genes in the gene sets | ||
+ | * The authors consider different magnitudes of the underlying effect size (i.e. log-fold-changes) | ||
+ | * The authors consider three null simulations (without regulation) as reference: | ||
+ | ** permutation of class labels | ||
+ | ** independently sampled expression of all features (=genes) | ||
+ | ** centering the simulated data, i.e. set effect size to zero | ||
+ | * In this publication, the authors published a novel simulation approach termed (FANGS) | ||
+ | * The simulation approach is available in this R package (FANGS) offers the opportunity to reproduce the simulations and repeat the analysis for other gene set methods. | ||
+ | * The authors provide a comprehensive list of the used configuration parameters | ||
+ | * The authors evaluated the following alternative configurations | ||
+ | ** For GSEA one alternative | ||
+ | ** For SAFE five alternative setups | ||
+ | ** For sigPathway and CAMERA no other configurations were considered | ||
+ | * Three experimental data sets were used as foundations for simulating data | ||
+ | ** prostate cancer (264 cases, 160 controls) | ||
+ | ** ischemic stroke (20 cases, 20 controls) | ||
+ | ** normal brain tissue (21 cases, 20 controls) | ||
==== Design for Outcome O1 ==== | ==== Design for Outcome O1 ==== |
Revision as of 10:00, 25 February 2020
Contents
1 Gene set analysis methods: a systematic comparison
Mathur, R., Rotroff, D., Ma, J., Shojaie, A., & Motsinger-Reif, A. , Gene set analysis methods: a systematic comparison, 2018, BioData mining, 11(1), 8.
1.1 Summary
Approaches for gene set analyses were assessed by using simulated data that were generated based on a real experimental data set.
1.2 Study outcomes
1.2.1 Outcome O1
The performance of ...
Outcome O1 is presented as Figure X in the original publication.
1.2.2 Outcome O2
...
Outcome O2 is presented as Figure X in the original publication.
1.2.3 Outcome On
...
Outcome On is presented as Figure X in the original publication.
1.2.4 Further outcomes
If intended, you can add further outcomes here.
1.3 Study design and evidence level
1.3.1 General aspects
- The authors compared four different methods:
- Gene Set Enrichment Analysis (GSEA)
- Significance Analysis of Function and Expression (SAFE)
- sigPathway, and
- Correlation Adjusted Mean RAnk (CAMERA).
- The authors consider different sizes of the gene sets
- The authors consider different proportions of regulated genes in the gene sets
- The authors consider different magnitudes of the underlying effect size (i.e. log-fold-changes)
- The authors consider three null simulations (without regulation) as reference:
- permutation of class labels
- independently sampled expression of all features (=genes)
- centering the simulated data, i.e. set effect size to zero
- In this publication, the authors published a novel simulation approach termed (FANGS)
- The simulation approach is available in this R package (FANGS) offers the opportunity to reproduce the simulations and repeat the analysis for other gene set methods.
- The authors provide a comprehensive list of the used configuration parameters
- The authors evaluated the following alternative configurations
- For GSEA one alternative
- For SAFE five alternative setups
- For sigPathway and CAMERA no other configurations were considered
- Three experimental data sets were used as foundations for simulating data
- prostate cancer (264 cases, 160 controls)
- ischemic stroke (20 cases, 20 controls)
- normal brain tissue (21 cases, 20 controls)
1.3.2 Design for Outcome O1
- The outcome was generated for ...
- Configuration parameters were chosen ...
- ...
1.3.3 Design for Outcome O2
- The outcome was generated for ...
- Configuration parameters were chosen ...
- ...
...
1.3.4 Design for Outcome O
- The outcome was generated for ...
- Configuration parameters were chosen ...
- ...
1.4 Further comments and aspects
1.5 References
The list of cited or related literature is placed here.